Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo
You may also be interested in...
Wide Data Gap On Generics Use In Japan Puts Damper On MHLW 30% Generic Target
TOKYO - A wide data gap on generics penetration between studies commissioned by Chuikyo and the Ministry of Health, Labor and Welfare has surfaced, casting clouds over the Japanese government's official target to raise generics use to 30 percent by 2012
Wide Data Gap On Generics Use In Japan Puts Damper On MHLW 30% Generic Target
TOKYO - A wide data gap on generics penetration between studies commissioned by Chuikyo and the Ministry of Health, Labor and Welfare has surfaced, casting clouds over the Japanese government's official target to raise generics use to 30 percent by 2012
Japanese Pharmas Agree To Lower NHI Prices When Generic Uptake Is Slow
TOKYO - Manufacturers would take "certain degrees of action" to lower national health insurance listed prices if generic penetration failed to reach a certain level in the same composite group during a drug's patented period, according to an industry proposal during the latest Chuikyo pharmaceutical price expert subcommittee meeting March 18